Starling Oncology signs $25M revolver with SLR Healthcare ABL; $4.75M drawn at close

Oncology Institute, Inc.

Credit agreement dated Aug 20, 2026; facility up to $25M, secured by substantially all SOM, LLC collateral.
$4.75M outstanding as of Aug 21, 2026 closing date; proceeds for working capital and general corporate purposes.
Maturity Aug 20, 2029; interest at Term SOFR (floor 2.00%) plus 3.95%, default rate adds 5.00%.
Borrowing base formula on receivables; covenants cap Maximum Loan Turn Days at 35 on rolling 3-month basis.
Fees include collateral monitoring 0.0833%/mo, unused line 0.04166%/mo, and termination fees up to 3%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.